Podcast: Why We Need to Discuss Gene Editing and Ethics
By Jack Murtha,
Healthcare Analytics News [with CGS' Marcy Darnovsky]
| 08. 03. 2018
In 1951, Henrietta Lacks walked into Johns Hopkins Hospital complaining of vaginal bleeding. Although she died later that year, her legacy lives on. Why? Because researchers took her cells and shared them with colleagues, conducting countless studies that have fueled findings in many areas. And they did so without her permission.
Henrietta’s story is incredible on several levels: First, her cells, transformed by radium, were unique in their ability not only to survive the laboratory but to thrive. Second, she unwittingly advanced medical and scientific research. Third, she never knew of her remarkable contribution to science, making her story a case study on consent, public trust and medical ethics.
>> READ: The Complicated Ethics of Gene Editing
Now, in 2018, gene editing is no longer the stuff of science fiction. It is real, and many gene-editing therapies, such as treatments involving chimeric antigen receptor T-cells and CRISPR, could forever change medicine. They could — no, they are ushering in the age of precision medicine. Their enormous costs have also contributed to the rise of value-based care, as certain therapies earn...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...